Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom

Aliment Pharmacol Ther. 2020 Sep;52(5):937-939. doi: 10.1111/apt.15951.

Mohammed Nabil Quraishi^{1

2}, Jonathan P Segal³, Rachel Cooney^{1

2}, Nicholas A Kennedy⁴, Rachel Ainley⁵, Naveen Sharma^{1

2}, Neeraj B Bhala^{1

2}, Matthew J Brookes^{6

7}

¹ Department of Gastroenterology, University Hospitals Birmingham, Birmingham, UK.
² College of Medical Sciences, University of Birmingham, Birmingham, UK.
³ Department of Gastroenterology and Hepatology, St Mary's, London, UK.
⁴ Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
⁵ Crohn's & Colitis UK, Hatfield, UK.
⁶ Department of Gastroenterology, Royal Wolverhampton Hospital, Wolverhampton, UK.
⁷ Research Institute in Healthcare Science (RIHS), University of Wolverhampton, Wolverhampton, UK.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804